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Abstract 
 
In this study we want to evaluate the potentiality of the use of a single chain Fv 
(scFv) for molecular imaging and therapy of Prostate Cancer. The target of this 
scFv is the Prostate Specific Membrane Antigen (PSMA), a type II 
transmembrane protein overexpressed in advances stages of this disease. In the 
past we have generated the murine antibody D2B recognizing hPSMA, whose 
diagnostic specificity has been investigated in xenograft murine models by 
imaging.  
In order to obtain a smaller protein able to better penetrate the tissues we 
decided to convert the murine monoclonal antibody D2B into a format like 
scFv. This format, due to its smaller size, have also the advantage, compare to 
the entire antibody, to have a faster clearance from the blood. 
The scFv has been constructed and its functionality has been tested with success 
on LNCaP cells. Using BIAcore (a technology able to measure the kinetic 
interaction between two molecules) we showed that the affinity of our scFv is 
still remarkable despite its monovalent binding. 
One goal of the present study is the assessment of potential role of this antibody 
fragment as diagnostic reagent for the development of radiopharmaceuticals for 
tumor characterization and molecular imaging. A second goal of the project is 
the production of a completely human antibody fragment against hPSMA in 
order to develop a reagent more suitable for therapy. We used phage display 
technology to convert the murine antibody in a human antibody applying 
guided selection technology which permits to generate an antibody with the 
specificity and functionality of the starting rodent mAb.  
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State of art 
 
Prostate Cancer (PCa), is the most common cancer in men in developed world, 
especially in western Europe and the Americas [Siegel et al. 2013] and has the 
highest incidence amongst male malignancies in Italy. 
The number of men diagnosed with PCa remains high despite the 5-year 
relative survival rates have increased dramatically over the years.  Since the 
beginning of the PSA era and the natural aging of the population, it has been 
observed a 25% reduction in the age-specific PCa mortality rate due to early 
detection screening programs but it has also been observed a dramatically 
increasing of the PCa worldwide incidence rate. Localized PCa is potentially 
curable with the use of one or a combination of modalities including 
brachytherapy, cryotherapy, external beam radiation therapy (RT), hormone 
therapy and/or radical prostatectomy (RP). However, in one-third of the patients 
the disease evolves into a more aggressive, metastatic and androgen-
independent form (AIPCa), which fails to respond to even multi-drug treatment. 
Some patients with AIPCa respond to secondary hormonal manipulations. 
Subsequently, the disease fails to respond to further hormonal therapy and it 
becomes Hormone Refractory Prostate Cancer (HRPCa) [Sonpavde et al. 
2006]. Therapy options for metastatic HRPCa remain limited. Therefore, in 
order to advance the treatment options for these tumors, other strategies for 
diagnosis and therapy are needed to improve the life expectancy of these 
patients. 
To date, we still lack the capacity for early diagnosis and prognostic tests 
allowing for the evaluation of aggressiveness. Imaging is a promising 
diagnostic/prognostic tool and identification of sensitive and specific agents is 
one of the major goals for PCa. Treatments for PCa with different way of action 
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and minimal toxicity are greatly desired and antibody therapy could answer to 
these requests. 
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1  The immune system 
 
The immune system is the body's defense against infectious organisms and 
other external agents. Through a series of steps that constitute the immune 
response, the immune system attacks organisms and substances that invade 
body systems and cause disease. The immune system is made up of cells and 
effectors molecules responsible for two different kinds of immunity: innate 
immunity and adaptive immunity; their main features are compared in Table 
1.1. Innate immunity (or non-specific immunity) does not require previous 
contact with the antigen and provides the early defense against microbes; it is 
created by the body's natural barriers, such as the skin, and protective 
substances in the mouth, the urinary tract, and on the eye surface. Another type 
of natural immunity is in the form of antibodies passed on from mother to child. 
Adaptive immunity (or specific immunity) is initiated by the specific 
recognition of antigens by lymphocytes; develops through exposure to specific 
foreign microorganisms, toxins, which are "remembered" by the body's immune 
system. When that antigen enters the body again, the immune system 
"remembers" exactly how to respond to it. Adaptive immunity is divided into 
humoral immunity (antibody mediated) and cell-mediated immunity. 
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 Innate Immunity Adaptive Immunity 
Components 
-Physical and chemical 
barriers 
-Phagocytic leukocytes 
-Dendritic cells 
-Natural Killer cells 
-Plasma proteins 
(complement) 
-Humoral immunity (B cells, 
which mature into antibody 
secreting plasma cells) 
- Cell-mediated immunity (T 
cells which mature into 
effector helper and cytotoxic T 
cells) 
Activity Always present Normally silent 
Response and 
potency 
Immediate response, but has 
a limited and lower potency 
Slower response (over 1-2 
weeks, but is much more 
potent) 
Specificity 
General: can recognize 
general classes of pathogens 
(i.e. bacteria, viruses, fungi, 
parasites) but cannot make 
fine distinctions 
Recognize highly specific 
antigens 
Memory 
No: reacts with equal 
potency upon repeated 
exposure to the same 
pathogen 
Yes: memory cells 
“remember” specific 
pathogens; upon re-exposure 
to a pathogen, these cells 
mount a much faster and more 
potent second response 
 
Tab. 1.1. Principal features of innate and adaptive immunity. 
 
1.1 Immunoglobulin structure and functions 
 
The production of antibodies or immunoglobulins (Ig) is one of the main 
functions of the humoral immune system. 
Antibodies could be expressed on the surface of B lymphocytes or secreted 
from plasma cells in the circulation and tissues. The antibody molecule, 
represented by IgG antibodies, is a 150 kDa tetrameric molecule with a 
symmetric structure composed of two identical heavy (H) chains and two 
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identical light (L) chains joined by disulphide bond
molecule (Figure 1.1.1). 
 
Fig. 1.1.1. Immunoglobulin G structure. 
 
Both H and L chains consist of amino-terminal variable (V) regions, so named 
because they contain regions of variability in amino acid sequence, that 
participate in antigen recognition and carboxy
that mediate effector functions. The heavy
CH and numbered sequentially from amino term
CH1, CH2, CH3 and also CH4 for IgE and IgM). The light chain constant 
domain is called CL. The hinge region located between CH1 and CH2 confers 
flexibility to the molecule.  
On the basis of differences in constant 
divided into distinct classes, called isotypes: IgA, IgD, IgE, IgG, and IgM 
depending on which heavy chain they contain (
classes, or isotypes, of CL: κ and λ. In humans, about 60% of antibody 
molecules have κ light chains, and about 40% have 
 
s to form a "Y" shaped 
 
-terminal constant (C) regions 
 chain constant domains are called 
inus to carboxyl terminus (e.g.  
domains, antibody molecules can be 
α, δ, ε, γ, µ). There are also two 
λ light chains. 
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Each antibody molecule, containing two heavy chains and two light chains, has 
two identical antigen-binding sites. 
In an antibody molecule, the heavy and light chain V region comprises three 
hypervariable regions called complementarity determining regions (CDR: 
CDR1, CDR2, and CDR3), responsible of the antigen-antibody binding spaced 
by four less variable regions called framework regions (FR: FR1, FR2, FR3, 
FR4), which support CDRs. Theoretically the antibody repertoire may include 
more than 109 different antibodies, each with unique amino acid sequences in 
their antigen-combining sites.  
Paul Ehrlich first proposed antibody therapy in 1900 as a magic bullet, but it 
takes more than 100 years (1997) before the first antibody had been approved 
by Food and Drug Administration (FDA) for human use. At present, more than 
20 antibodies are FDA approved and hundreds of new antibodies and antibody-
derived reagents are in clinical trials.   
We can recognize at least 4 biotechnological steps that make these results 
possible: Hybridoma Technology (in 1975 Köhler and Milstein), Polymerase 
Chain Reaction (PCR) discovery [Mullis and Faloona 1987], Transgenic Mice 
generation [Gordon and Ruddle 1981] and Phage Display Antibody Library 
[McCafferty et al. 1990]. 
The use of these technologies have allowed the conversion of existing mouse 
mAbs (from hybridoma technology) into mouse-human chimeric antibodies 
greatly refining and expanding the therapeutic potential of the modality of 
treatment. Chimeric antibodies are obtained by joining the antigen-binding 
variable domains of a mouse mAb to human constant domains. Humanized 
antibodies are created by grafting the antigen-binding loops, (CDRs), from a 
mouse mAb into a human IgG (figure 1.1.2).  
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Chimeric and humanized mAbs used in human clinical trials showed a variable 
degree of immunogenicity: chimeric mAbs in general show better 
pharmacokinetics and less immunogenicity than mouse mAbs but patients 
eventually tend to develop levels of HAMA comparable with those observed 
with mouse mAbs, indicating that the immunogenicity of chimeric mAbs can 
vary greatly in a way not yet predictable and can be directed against the mouse 
V region with characteristic of an anti-idiotypic response. The ideal reagent for 
human therapy could be a completely human antibody even if recent studies 
have demonstrated that many human and humanized antibodies trigger the 
development of anti-drug antibody responses and infusion reactions. 
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Fig. 1.1.2. Antibodies in clinical development. A) Mouse antibody; b) Chimeric 
antibody; c) Humanized antibody; d) Human antibody (Pictures from Frigerio 
et al, 2010). 
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The modular domain architecture of immunoglobulins has been exploited by 
protein engineering to create a wide variety of functional antigen-binding 
fragments that differ in molecular-weight (from 12 to 150 kDa) and in valency 
(n), from monomeric (n=1) to tetrameric (n=4) and possibly higher. The Fab 
format (fragment antigen binding), achievable either by proteolytic cleavage or 
protein engineering, contains two polypeptidic chains composed of two 
domains, VHCH1 and VLCL with an interchain disulfide bond at the terminal 
of each constant domain (molecular weight around 60 kDa). At present the 
most frequently used building block used to create novel antibody formats is the 
single-chain variable (V)-domain (scFv) consisting of a single polypeptide (30 
kDa) formed by the variable regions of the heavy and light chains joined by a 
peptide linker of up to ~15 amino acid residues. The variable heavy and light 
domains can be assembled also as Fv, without a linker peptide, exploiting their 
natural hydrophobic interaction but this is much less stable than scFv and could 
not be used in vivo. Examples of possible antibody formats are showed in figure 
1.1.3. 
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Fab(Fab)2 Fv scFv
VH VL
Diabody Nanobody / Single domain
a)
b)
 
Fig. 1.1.3. Schematic representation of antibody formats (Pictures from Frigerio 
et al, 2010). 
 
1.1.1 Nanobodies 
 
In addition to the conventional antibodies, in the early 1990s, it was discovered 
that llamas, camels, dromedaries, nurse and wobbegong sharks produce 
antibodies composed only of heavy chains [Harmsen and de Haard 2007]. 
These antibodies are referred to as heavy-chain antibodies (hcAbs) and the 
antigen-binding site is formed only by a single domain, designated VHH in 
camelid and VNAR in shark and more generally, nanobody or single domain 
antibody (sdAb). The hcAbs have also been described in human as a 
pathological disorder termed “heavy chain disease” [Wahner-Roedler and Kyle 
2005]. Despite the absence of light chain and their small size (15 kDa), 
nanobodies show a binding affinity for their cognate antigens in the range of 
affinities that are described for conventional antibodies. 
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The characteristics of nanobodies offer a number of technological advantages in 
the generation of engineered antibodies, as compared with conventional 
antibodies because are more soluble and stable than their larger counterparts. 
Nanobodies can get deep into tissues or cross the blood brain barrier where they 
have the potential to neutralize viruses or deliver toxins to cancer cells [Saerens 
et al. 2008]. 
Finally single-domain antibodies could be used as building blocks for novel 
therapeutics in a wide range of formats, including unique multivalent (multiple 
nanobodies with identical binding sites for the same antigen), biparatopic (two 
nanobodies binding two different epitopes on the same antigen), bispecific 
(nanobodies binding to two different antigens), bifunctional molecules [Satta et 
al. 2013] and chimeric antigen receptors (CARS) [Kloss et al. 2013]. 
 
2  Prostate Cancer 
 
The main function of prostate is to produce seminal fluid. Normal prostate 
gland is histologically divided into the stroma and the epithelium. Stroma 
contains the smooth muscle component of the prostate gland; the epithelium 
contains the glands. Glandular epithelium, which gives rise to prostate 
adenocarcinoma, is composed of three distinct cell types:  
- secretory luminal cells: are the predominant cell type, produce prostatic 
secretory proteins and are androgen-dependent cells [Brawer et al. 1985] [Nagle 
et al. 1987] [Verhagen et al. 1988] [Sherwood et al. 1991] [Liu et al. 1997]; 
 -  basal cells:  express androgen receptor (low level) [Brawer et al.1985] 
[Nagle et al.1987] [Verhagen et al.1988] [Sherwood et al.1991] [Liu et 
al.1997] [Bui and Reiter 1998] and factors that protect from DNA damage [Bui 
and Reiter1998] [De Marzo et al. 1998];  
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- neuroendocrine cells: are androgen-independent cells and seem to provide 
paracrine signals that support the growth of luminal cells [di Sant'Agnese 2001]  
[Abrahamsson 1999].  
 
2.1 Prostate Cancer diagnosis and standard treatment 
 
At present, only biopsy (transrectal ultrasound (TRUS)-guided biopsy) from the 
prostate can establish the diagnosis of PCa. However, the ability of TRUS to 
delineate small cancer foci and differentiate between benign prostatic 
hyperplasia (BPH), atrophy, inflammatory processes and malignancies is 
limited.  
Even if approximately 20% of patients are first diagnosed as having advanced 
carcinoma, in the great majority of cases the onset of PCa remains confined to 
the organ. Surgery and radiotherapy can efficiently treat organ-confined 
disease; however, in one-third of the patients, the disease evolves into a more 
aggressive, metastatic and androgen-independent form, which fails to respond 
to even multi-drug treatment. 
In the early stages PCa grows in an androgen dependent form and the main 
therapeutic intervention consists of androgen ablation by pharmaco-therapeutic 
or surgical (orchiectomy) approaches.  
Pharmacological methods for achieving androgen ablation are represented by 
administration of different compound: the Luteinizing-Hormone-Releasing 
Hormone (LHRH), the imidazole derivative ketoconazole and estrogens (such 
as diethylstilbestrol). The therapy is very effective in androgen-dependent 
cancer as a means of improving the quality of life and preventing or delaying 
the transition of cancer cells to AIPCa [Feldman and Feldman 2001], but these 
cancers eventually become androgen independent, progress and metastasize. 
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Food and Drug Administration (FDA) have approved four agents (Zoledronic 
Acid, Mitoxantrone, Docetaxel and DenosuMab) for the treatment of patients 
with AIPCa. 
Zoledronic Acid and Mitoxantrone were approved basically as palliative, while 
Docetaxel is the only chemotherapeutic agent approved given a demonstrated, 
although modest, survival benefit [Petrylak et al. 2004] [Tannock et al. 2004]. 
DenosuMab is a fully human monoclonal antibody (mAb) of the IgG2 subtype 
used for the prevention of skeletal-related events in patients with bone 
metastases from solid tumors. DenosuMab binds RANK ligand, preventing it 
from binding to the RANK receptor, and therefore inhibiting osteoclastogenesis 
and subsequent bone resorption [So et al. 2012]. 
Even if some patients with AIPCa respond to secondary hormonal 
manipulations, the disease fails to respond to further hormonal therapy and 
becomes HRPCa [Sonpavde et al.2006]. 
Therapy options for HRPCa remain limited. Therefore, in order to advance the 
treatment options for these tumors, other strategies for diagnosis and therapy 
will be needed to improve the life expectancy of patients with this disease. 
 
2.2 Molecular imaging of Prostate Cancer 
 
The conventional imaging techniques used for PCa diagnostics are ultrasound, 
computerized tomography (CT), radiography and magnetic resonance imaging 
(MRI). These techniques can offer morphologic tumor information but are less 
powerful for staging and disease monitoring. Consequently, newer imaging 
approaches able to detect pathological processes in tumor cells are used and 
include positron emission tomography (PET) and single photon emission 
computerized tomography (SPECT).  
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The use of radiolabeled molecular probes targeting tumor characteristics, such 
as increased glucose metabolism, cell proliferation or fatty acid synthesis, can 
provide key molecular and functional information on tumor.  
Metabolic tracers are used in PCa however, their non-specificity for this disease 
has stimulated the development and evaluation of PCa specific molecular 
imaging probes. The most clinically used radiotracers are FDG, choline and 
FLT. 
18F-fluorodeoxyglucose (FDG) is a glucose derivative and is the standard 
radiopharmaceutical in oncologic PET imaging. FDG internalize into the cell 
through specific glucose transporters (GLUTs) and is phosphorylated by 
hexokinase. Phosphorylated FDG cannot further undergo glycolysis and is 
trapped in the cells [Emonds et al. 2009]. Based on the Warburg effect in which 
the tumor cells metabolism is increased, FDG resulted a very successful tracer 
in clinical oncology; however results are partially disappoint in PCa patients, 
most likely because a  low glucose metabolism is generally observed in well-
differentiated PCa. Further, renal excretion, accumulation in the bladder, 
androgen ablation limits the diagnosis of PCa [Emonds et al.2009]. 
Choline is a water-soluble essential nutrient that was discovered in 1864 by 
Adolph Strecker. Choline is the precursor for phospholipid synthesis, 
transmembrane signaling and lipid–cholesterol metabolism/transport. In PCa  
an elevation of phosphatidylcholine has been demonstrated [Ackerstaff et al. 
2001]. Radio-labeled choline derivates, such as 11C-choline, 18F-fluorethyl-
choline or 18F-fluormethyl-choline, have been employed in several patient 
studies. Choline is able to detect more accurately nodal PCa spread due to a 
reduced renal excretion. Also, detection of primary tumors as well as restaging 
in patients with biochemical relapse has been performed with promising results 
[Rinnab et al. 2007]. However, Sutinen et al. (2004) demonstrated that the use 
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of 11C-choline is limited because is not able to distinguish PCa from hyperplasic 
prostate tissue.  
3-Deoxy-3′-[18F]fluorothymidine ([18F]-FLT) is a thymidine analogue used in 
PET imaging [Pascali et al. 2012]. The rate-limiting enzyme for the uptake 
of 18F-FLT is the thymidine kinase 1 (TK1). TK1 activity has been shown to be 
high in proliferating cells and is mainly activated in the S-phase. Despite 
several studies, the exact role of FLT in the imaging evaluation of response to 
treatment in men with PCa awaits more extensive studies. A complicating 
factor is also the physiologically high level of marrow FLT uptake that can 
hinder bone lesion detection and assessment. 
 
2.3 Immunotherapy with monoclonal antibodies 
 
Several characteristics of PCa make it an excellent target for immunotherapy 
with mAbs [Bander et al. 2003]: 
• prostate is a relatively non-essential organ; 
• PCa has a very strong tendency to spread to the bone marrow and lymph 
nodes, locations that receive high levels of circulating antibody and have 
proven responsive to mAb therapies in other tumor types (e.g., lymphoma, 
breast cancer);  
• PCa metastases are typically of small volume allowing for good antibody 
penetration and antigen access; 
• PCa has generally a slow proliferative index, allowing ample time for an 
immunotherapy to induce and potentiate T-cell-mediated immunity against 
the tumor [Sowery et al. 2007]. 
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2.4 Prostate cancer immunotherapy 
 
Immunotherapy comprises both active and passive treatment approaches and 
could provide elimination of cancer cells without harming normal tissue and, 
therefore, with no or very few side effects showing great promise for improving 
the survival of patients.  
Active immunotherapy or vaccines aim to elicit or increase tumour-reactive 
antibodies or lymphocytes, rather than supply these exogenously. Vaccines 
include injection of purified antigens, defined peptide fragments of specific 
antigens or the expression of antigens by viral vectors. Protein antigens and 
peptides must be injected together with adjuvant to improve the processing and 
presentation of the antigen by dendritic cells (DCs) and to provide a depot 
effect. Alternatively, DCs are loaded with antigen ex vivo prior to injection.  
The term passive immunotherapy describes ex vivo generation of effector 
molecules (e.g. mAbs, cytokines), or effector cells (e.g. CD8+ T cell) that are 
then transferred to the patient. Antibodies may: 1) block important growth 
factors or growth factor receptors on cancer cells or directly induce apoptosis of 
the cancer cell; 2) activate components of the immune system via the Fc-region 
of the antibody; 3) activate the antibody dependent cell-mediated cytotoxicity 
(ADCC) that is executed by macrophages, NK cells and probably granulocytes. 
In the contest of PCa, the immunotherapic strategies are therapeutic vaccination 
and immune checkpoint blockade. Therapeutic vaccination include the use of 
PSA or PAP (prostatic acid phosphatase) using a variety of strategies such as 
APC (antigen presenting cells), genetically modified tumor cells, viral-based 
vectors, peptide and DNA [Ahmad et al. 2012]. Therapeutic cancer vaccination 
is often enhanced by the coadministration of a cytokine adjuvant such as GM-
CFS (granulocyte-macrophage colony stimulating factor). Therapeutic 
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vaccination strategies used for PCa that seems to show some clinical promise 
are exemplified by sipuleucel-T and PROSTVAC-VF. Sipuleucel-T 
(PROVENGE, Dendreon Corp.) is an autologous vaccine prepared using 
patient’s peripheral blood mononuclear cells (PBMC) cultured with a fusion 
protein consisting of PAP and GM-CSF and re-infused into the patients. 
PROSTVAC-VF (BN ImmunoTherapeutics) is a poxvirus-based vaccine 
engineered to contain PSA and 3 immune co-stimulatory molecules within a 
vaccinia virus or fowl pox virus vector. For PCa immune checkpoint blockade 
includes the use of mAb Ipilimumab for blocking CTLA-4 (anticytotoxic-T-
lymphocyte associated antigen 4) and mAbs for blocking PD-1 (programmed 
death 1).  
 
2.5 Target choice 
 
Suitable target antigens for therapeutic antibodies are considered those 
molecules that are [Ross et al. 2005]: 
• crucial to the malignant phenotype; 
• not significantly expressed in vital organs and tissues; 
• reproducibly measurable in clinical samples; 
• well correlated with the clinical outcome. 
Therefore interference or inhibition of such antigen should yields a clinical 
response  in a significant number of patients expressing the target antigen, with 
minimal to absent responses in patients whose tumors do not express the target. 
In addition, for drugs conjugated antibody, the target must be located on the cell 
surface and, when complexed with the therapeutic antibody, should internalize 
to facilitating tumor cell killing. 
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3 Prostate Specific Membrane Antigen (PSMA)
 
The PSMA gene, located on chromosome 11p
class II transmembrane glycoprotein [Pinto
cytoplasmic tail of 19 amino acids, a single hydrop
domain of 24 amino acids, and a large extracellular domain 
at the COOH terminus (Figure 3.1) [Olson
Alternative PSMA isoforms, consequence of alternative splicing of the PSMA 
gene, includes PSM’, PSM-C and PSM
newly discovered PSM-E [Cao et al. 2012]
 
Fig. 3.1. PSMA structure.  
 
PSMA is a carboxypeptidase with two important enzymatic functions: folate 
hydrolase and NAALADase (N-acetylated 
shows an endocytotic function [Ghosh et al.
non-covalently linked homodimer with a compact three
on the cell surface of prostate epithelial cells 
 
 
 [Israeli et al. 1994] encodes for a 
 et al. 1996] with a NH2-terminal 
hobic transmembrane 
of 707 amino acids 
 et al. 2007]. 
-D [Schmittgen et al. 2003] and the 
. 
 
α-linked acidic dipeptidase) and also 
 2005]. PSMA is expressed as a 
-dimensional structure 
[Mesters et al. 2006]. 
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The enzymatic activity of PSMA is dependent on glycosylation of its 
extracellular domain and dimerization for proper function. Homodimerization is 
a fundamental feature of many transmembrane receptors. Homodimer formation 
is often induced by ligand binding, which is in turn necessary for mediating the 
cellular response of the receptor. PSMA undergoes endocytosis from the 
plasma membrane. This endocytosis occurs through clathrin-coated pits and 
involves the first five NH2-terminal amino acids of the cytoplasmic tail. 
Antibodies can induce PSMA internalization and the accumulation in the 
recycling endosomal compartment support the hypothesis that PSMA might 
function as a receptor internalizing a putative ligand. The capability of PSMA 
to internalize is a prerequisite for the delivery of cytotoxic agents. 
PSMA expression has been demonstrated in normal prostate and Benign 
Prostate Hyperplasia (BPH), in Prostatic Intraepithelial Neoplasia (PIN) and in 
invasive adenocarcinoma and in the neovasculature of various non prostatic 
epithelial malignancies [Wright et al. 1995]. PSMA expression and enzymatic 
activity are increased in PCa: PSMA expression density increases progressively 
in PIN versus normal prostate epithelium, in higher grade versus lower grade 
carcinomas, in locally advanced versus organ confined tumours, in metastatic 
versus primary lesions and in hormone-independent versus hormone-dependent 
tumors [Wright et al.1995] [Israeli et al. 1993] [Wright, Jr. et al. 1996] [Sweat 
et al. 1998]. 
Indeed PSMA has been correlated with aggressive disease [Rajasekaran et al. 
2005]. In addition to its prostate gland expression, PSMA is also expressed by 
cells of the small intestine, proximal renal tubules, salivary glands and central 
nervous system, albeit at levels 100 to 1000 fold less than by prostate 
epithelium. The restricted expression of this molecule, which is not secreted, 
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has made PSMA an ideal target for anti-PSMA antibody therapy [Ghosh et 
al.2005] [Ross et al. 2003] [Lapidus et al. 2000]. 
7E11 was the first anti-PSMA monoclonal antibody developed and labeled with 
111In; the commercial name of 7E11 is Prostascint and received Food and Drug 
Administration (FDA) approval in 1996 for use as a diagnostic tool for PCa 
[Israeli et al.1994]. The 7E11 mAb recognize the cytoplasmic portion of PSMA 
[Barren, III et al. 1997]. 
Consequently, newer generation of antibodies has been identified for 
therapeutic purposes based on their recognition of the extracellular domain. 
The J591 mAb [Chang et al. 1999] directed against the extracellular domain of 
PSMA has been most investigated and clinical trials have been conducted with 
this antibody using a variety of radiolabeled and toxin conjugates. In addition, 
other antibodies targeting PSMA are being developed and evaluated. 
As above described, PSMA has been targeted by several mAbs and some have  
already entered in clinical trials [Olson et al.2007].  
Shim et al in 2011 demonstrated, for CD20 and HER2,  that different antibodies 
targeting the same antigen can differ widely from one another in terms of 
biological, clinical characteristics and modes of action justifying our attempt to 
develop new anti-PSMA mAbs. 
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4 Phage display  
 
Phage display technology consists in the selection of peptides and proteins from 
combinatorial libraries displayed on the surface of filamentous phage
[McCafferty et al.1990]. This methodology is becoming an important tool in 
biotechnology for the generation of diagnosti
al. 1998] and for the study of natural immune responses
this technology is the linkage of displ
encapsulated genotype which allows the evolution of the selected binders into 
optimized molecules and permits the rapid determination of the aminoacid
sequence of the specific binding peptide or protein m
sequencing of the specific insert in the phage genome (Frigerio 
 
Fig. 4.1. ScFv expression on the surface of the filamentous phage
from Frigerio et al, 2010). 
 
4.1 Phage antibody libraries 
 
Human antibody fragments against a variety of antigens could be isolated from 
diverse human antibody libraries. There are 
naïve, synthetic and immune. Naïve libraries are composed by 
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variable genes isolated from healthy donors or non-immunized animals. In 
synthetic libraries a combinatorial diversity is created by rearranging VH and 
VL gene segments in vitro and introducing artificial CDRs of varying loop 
lengths using PCR and randomized primers. Immune libraries are constructed 
using antibody V genes obtained from immunized animals, vaccinated patients 
or from patients that responded to a specific disease. 
 
4.2 Guided selection 
Guided selection is a method for producing a human version of a rodent or any 
other non-human antibody. The procedure to obtain a completely human 
antibody (Fig.4.2.1) is performed as follows: 
First step: a human VHCH phage library is used to infect Escherichia Coli 
containing the VLCL domain of the starting monoclonal antibody and 
production of a pool of phages expressing a different human heavy chain paired 
with the same murine light chain. The light chain will guide the selection of a 
partner human heavy chain that binds the same epitope area on the antigen as 
the original mouse antibody.  
Second step: a) binding of phages to the immobilized target antigen b) removal 
of non specifically bound phages by washing c) elution of specifically bound 
phages d) amplification of phage library by infection and propagation of eluted 
phages in Escherichia coli e) use the new phages produced for next panning 
cycles. This procedure is called panning and allows the enrichment of those 
phages able to bind the immobilized target. Panning could be performed using 
immobilized antigen, antigens in solution and directly on cells or in vivo. 
Third step: the corresponding genes of the human VHCH selected by panning 
are cloned into a phagemid vector containing a repertoire of human VLCL 
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domains. Phages expressing the same human VHCH but different human 
VLCL are selected as previously described.  
 
Fig. 4.2.1. Schematic representation of guided selection procedure. 
 
The endpoint of this sequential chain shuffling procedure is a set of completely 
human antibodies, binding with high probability to the same epitope on the 
antigen as the original mouse antibody. 
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Aim of the project 
 
Imaging is a promising diagnostic and prognostic tool and the 
identification of sensitive and specific agents is one of the major goals for PCa: 
in this field mAbs represent ideal targeting agents. Towards this aim, PSMA, a 
well-known tumor associated antigen, has been targeted by several mAbs and 
some are currently in preclinical and clinical studies for both diagnostic and 
therapeutic applications [Nelson et al. 2010]. Overall, whole mAbs show 
several problems for their clinical applications. Antibody uptake by the tumor 
depends on a balance between favourable pharmacokinetics and efficient 
penetration and retention in the targeted tissue, and various characteristics of 
mAbs, such as molecular size, shape, affinity and valency control these 
properties. MAbs are large molecules that are characterized by very long serum 
half-lives. They far exceed the renal clearance threshold (~70 kDa), preventing 
them from being eliminated through the kidney glomeruli. Moreover, the Fc 
domain of antibodies can interact with various receptors expressed at the 
surface of several cell types, which increase their retention in the circulation. 
Most importantly, the Fc portion can interact with the neonatal Fc receptor 
(FcRn) expressed at the surface of several cell types, including vascular 
endothelium cells, monocytes and macrophages as well as with barrier sites 
such as the blood–brain interface, the glomerular filter in the kidneys and the 
intestinal epithelium [Roopenian and Akilesh 2007]. ScFv fragments, due to 
their smaller size can more easily penetrate in solid tumor masses and the 
absence of the CH2-CH3 domains involved in neonatal Fc receptor binding  
allow a rapid clearance from the blood theoretically achieving a much greater 
target specificity for tumor localization [Yokota et al. 1992], moreover, using a 
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scFv fragment, the Human Anti Mouse Antibody (HAMA) response could be 
reduced being the Fc the most immunogenic component of the molecule. 
 
The first aim of the project was the production and characterization of a murine 
scFv starting from the monoclonal antibody D2B and the following objectives 
were finalized: 
- Conversion of the murine IgG monoclonal antibody D2B into a scFv 
format; 
- Set up the scFv production in prokaryotic cells and verification of the 
stability of the reagent; 
- Analysis of the specificity and affinity for PSMA expressing cells; 
- Set up of the scFv radiolabelling procedures with different 
radioisotopes; 
- In vivo preclinical validation of scFvD2B suitability for molecular 
imaging. 
 
The second aim of the project was the creation of a completely human antibody 
fragment starting from the monoclonal antibody D2B using guided selection 
(described in Part III of this thesis). 
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Results and Discussion 
 
1 ScFvD2B construction and production 
 
A new mAb directed against hPSMA antigen and named D2B (IgG1) was 
obtained by conventional hybridoma technology. 
The cDNA obtained by reverse transcriptase of mRNA extracted from the 
mouse hybridoma D2B was amplified by PCR using the corresponding primers 
for VH and VL regions. These fragments were sequenced and showed to 
correspond to a VH and a VL (kappa type) regions of mouse Igs. The murine 
D2B use a V segment of the VK1 family (12/13 subgroup) and VH3 family. 
Kabat numbering was used to identify the three CDRs of the antibody [Martin 
2001].  
The variable regions, after re-amplification with primers for the insertion of 
restriction enzyme sites, were cloned into pMIMO vector and the scFv, 
produced in soluble form in the periplasm of bacteria cells, was purified on 
immobilized-metal affinity chromatography, by incubating the periplasmic 
extract with Ni-NTA agarose beads. The overall yield of anti-PSMA scFvD2B 
in Escherichia Coli was up to 12-14 mg/L. The size and the integrity of the 
purified reagent was visualized on a Coomassie-stained SDS-PAGE and 
detected by Western-blot with 9E10 antibody. ScFvD2B migrated as a single 
band of the expected molecular size of about 28 kDa.  
ScFvs are relatively unstable [Cheng et al. 2003] and reported to form dimers 
and aggregates [Arndt et al. 1998] [Rothlisberger et al. 2005] following 
purification, particularly if they are derived from hybridoma cells [Kipriyanov 
et al. 1997]. This is due to many factors which include the presence of a 
disulfide bridge in the VH and VL domain, exposed hydrophobic patches at the 
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variable/constant domain interfaces, ionic strength, pH, linker length and at last 
the primary sequence, which is the most causative factor which affects the 
aggregation tendency [Ramm et al. 1999] [Nieba et al. 1997] [Arndt et al.1998] 
[Pluckthun et al, 1996]. Moreover the nature and strength of the VH-VL 
interface interactions and the type of linker used [Huston et al. 1991] [Raag and 
Whitlow 1995] [Whitlow et al, 1991] increase the risk for aggregation [Arndt et 
al. 1998][Rothlisberger et al. 2005]. 
To evaluate the potential formation of dimers or aggregates, that could increase 
the immunogenicity of the reagent limiting its use for clinical practice, 
scFvD2B was analyzed by gel filtration on size-exclusion column indicating 
that at least 95% consisted of monomeric molecules (28 kDa) (Fig. 1). In 
addition, probably due to a very stable pairing of the variable chains, scFvD2B 
could be produced on a laboratory scale with good yield. 
 
2 ScFvD2B binding specificity 
 
The binding specificity of scFvD2B against the antigen of interest (PSMA) in 
native form was verified by FACS analysis in comparison with its parent mAb 
using different cell lines expressing (LnCaP, PC3-hPSMA also called PC3-PIP, 
MCF7-hPSMA, CHO-hPSMA) or not-expressing (PC3, MCF7, CHO) PSMA. 
Both IgGD2B and scFvD2B showed a good and specific binding to the cell 
lines expressing the antigen whereas the non-related cell lines were negative 
(Fig. 2). ScFv binding is lower than the whole antibody as expected for a 
monovalent antibody fragment but shows a high binding strength demonstrated 
by a shift in fluorescence activity of only 1 log. Similar results were obtained 
when both reagents were fluorescinated or labeled with biotin followed by 
fluorochrome labeled avidin (data not shown) indicating also that our reagent is 
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suitable for a wide range of manipulations without losing its specific binding 
capability.  
ScFvD2B used in immunohistochemistry (IHC) is able to recognize PSMA 
expressed on tumor surgical specimens reacting only with the tumor areas and 
did not stain any surrounding healthy tissue (Fig. 3A) indicating that our 
reagent could be suitable as diagnostic\ therapeutic agent.  
BIAcore analyses, performed using as ligand soluble PSMA from lysates of 
LnCaP or PC3-PIP cells captured using the monoclonal antibody 7E11 specific 
for the intracellular domain of PSMA, showed that scFvD2B, despite its 
monovalency, retained a good binding strength (Fig. 3B, left panel). The lower 
RU observed in the sensogram with the scFv is attributable to its size, which is 
6 times lower than that of the whole IgGD2B.  
Based on the experimental data, association and dissociation-curves were 
calculated (black lines) and kinetic evaluations are summarized in Figure 3B, 
right panel; despite its monovalent binding, scFvD2B shows an affinity 
constant (KD) of 8.6 nM which is 20 times lower than that of IgGD2B, but 
comparable to that of the anti PSMA IgGJ591 (1.8, 3 and 15 nM in three 
different reports [Smith-Jones et al. 2000] [McDevitt et al. 2000] [Fracasso et 
al. 2002]), already entered in clinical use [Akhtar et al. 2012]. The very slow 
dissociation constant from the antigen argues for a high in vivo binding stability 
of scFvD2B on the PSMA. Moreover, the high affinity retained by scFvD2B 
indicate the possibility to use a scFv for targeting thanks to its very quick 
attachment to the antigen combined with a stable binding for a suitable length 
of time on the target and also thanks to its rapid clearance. Many studies have 
been performed about the importance of the best antibody formats for in vivo 
uses indicating that reducing the circulation time the affinity must be improved 
to obtain productive results [Leyton et al. 2008] [Lepin et al. 2010].  Our 
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scFvD2B with its high binding strength is promising for have a rapid 
localization despite a very fast clearance. 
 
3 Radiolabeling 
 
As previous described, for protein therapeutics including mAbs, the formations 
of aggregates can strongly limit in vivo applications since they may reduce the 
mAb efficacy and contribute to immunogenicity. The integrity of scFvD2B 
after radiolabeling, evaluated by SDS PAGE (Fig. 4), was more than 99% and 
the formation of dimers (visualized using size-exclusion column) was less than 
3% for 131I-scFvD2B and less than 5% for 111In-scFvD2B (data not shown).  
All the data obtained with scFvD2B indicate that more than 95% of the reagent 
after radiolabeling procedure is composed of monomeric protein.  This is even 
more important infact for this reason the purification after labelling could be 
avoided making possible the development of a simple labelling kit accessible to 
all Nuclear Medicine facilities.  
After radiolabeling of scFvD2B with 111In and 131I,  a radiolabeling efficacy of 
96% was measured with a good radiochemical purity. The immunoreactivity of 
the reagents were tested on cell expressing PSMA both natural (LnCap) and 
ectopically expressed (PC3-PIP). No binding was observed on PC3 cells. Table 
1 summarizes the efficiency of radiolabeling with 111In and 131I, the 
radiochemical purity, the specific activity and the immune reactivity for 
scFvD2B and IgGD2B.  
The availability of radiolabeled reagents with high immunoreactivity allows the 
development of quantitative competition and internalization assays.  
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4 Competition assay 
 
IgGD2B and scFvD2B were analyzed for the competition capacity with other 
two anti-PSMA antibody commercially available: IgGJ591 (recognizing an 
extracellular epitope of PSMA) and IgG7E11 (recognizing an intracellular 
epitope of PSMA). The radiolabeled reagents (scFvD2B and IgGD2B) with 
competing unlabeled antibodies (scFvD2B, IgGD2B, IgG7E11 and IgGJ591) in 
serial dilutions are mixed in solution and added on fixed PC3-PIP cells.  
After three hours of incubation and washes, the radioiodinated antibodies bound 
to the antigen were detected in a γ-counter to count the residual binding 
activity. The inhibiting concentration of 50% (IC50) of 131I-scFvD2B or 131I-
IgGD2B binding was extrapolated from titration curves calculating the ratio 
between the residual binding after the competition assay and the binding of the 
radiolabeled antibodies alone. Unlabeled scFvD2B and IgGD2B (Fig. 5A) are 
able to compete with binding of 131I-scFvD2B on PC3-PIP cells; the mean 
inhibitory concentration (IC50) calculated for both unlabeled reagents was 1:1 in 
molar ratio. Unlabelled scFvD2B and IgGD2B compete also with radiolabeled 
131I-IgGD2B (in similar manner of 131I-scFvD2B) but not with IgG7E11 and 
IgGJ591 (Fig. 5B).  
The data obtained suggest that the binding strength of scFvD2B and IgGD2B 
are quite similar and that both recognize an extracellular epitope different from 
that recognized by IgG7E11 (as expected being an intracellular epitope) and by 
IgGJ591.  
 
 
 
 
Barbara Frigerio 
 
33 
 
5 Stability  
 
The scFvD2B was further analyzed to evaluate its stability in different 
experimental conditions. An important feature of antibodies for potential 
diagnostic and therapeutic applications is a sufficient resistance to serum 
proteases; we have evaluated its stability in mouse and human serum. The 
results are summarized in Fig. 7 as residual binding activity assessed by ELISA 
(cold reagent) or RIA (radiolabeled reagent). Incubation for 6 hours in mouse 
sera and for 24 hours in human sera, both potentially containing proteases, did 
not affected neither integrity, as assessed by SDS-PAGE (Fig. 6), nor binding 
activity of scFvD2B (Fig. 7). It is well known that the formations of dimers and 
aggregates can limit the in vivo applications of protein therapeutic for the 
reduction of mAbs efficacy and the increase of immunogenicity. For this reason 
the second feature analyzed is the stability of scFvD2B after long storage that 
could increase aggregate formation or loss of functionality. After storage for 
more than one year (18 months) at -20°C we observed a good maintenance of 
functionality (Fig. 8) and no aggregate formation, indicating a good thermo-
stability. 
The last analyzed characteristic was the stability of scFvD2B under typical 
conditions used for the radiolabeling of the reagent: resistance to neutral and 
acidic condition (i.e. Hepes 1M pH 3.5 and CH3COONa 0.4M pH4) and 
resistance at physiological (37°C) and high temperature (42°C, Fig. 9). 
ScFvD2B maintains its specific binding to cells expressing PSMA also after the 
exposure to physiological and harsh conditions, such as low pH (Fig. 10) and 
different range of temperature indicating that our reagent could be subjected to 
chemical manipulations without loss of binding activity. 
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6 Internalization of antigen-antibody complex 
 
The target antigen characteristics and the fate of antigen-antibody complex after 
antibody binding are important features for the success of imaging and selection 
of therapeutic agents (radioisotopes, drugs and toxins). 
PSMA-mediated antibody internalization was evaluated by epifluorescence 
analysis (Fig. 11A) and quantified by a radiolabel internalization assay (Fig. 
11B). Both evaluations were performed at 37 °C in order to activate the 
internalization machinery and allow the PSMA-bound scFvD2B or IgGD2B to 
internalize. The same experiment was also performed at 4°C as control in order 
to prevent the internalization. 
The internalization of the antibodies evaluated by immunofluorescence 
indicated that substantial amount of a surface-bond anti-PSMA scFvD2B and 
IgGD2B was transferred to intracellular sites at 37°C (Fig. 11A, left panel), in 
contrast internalization performed at 4°C (right panels) shows a reduced 
internalization of antibodies in the cells expressing PSMA highlighted by 
PSMA expression in membrane surface. 
The kinetics of PSMA internalization mediated by the two reagents, 
radiolabeled with 111In (Fig. 11B), were similar; after 5 minutes at 37 °C from 
20% to 60% of antigen-antibody complex was internalized and, thereafter, the 
amount of internalized PSMA increased over time reaching a plateau in less 
than 2 hours. When the internalization triggering reagent was the scFvD2B, the 
total amount of internalized complex was lower at each observation point but its 
monovalent binding was able to internalize around 40% of the bound antigen in 
2 hours. Similar internalization ability was recorded when the scFvD2B was 
radiolabeled with 131I using a different chemistry of labeling (data not shown). 
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This observation would be consistent with the interpretation that the bivalent 
binding of IgGD2B crosslinking of two copies of PSMA leads to a more potent 
internalization than binding by a monovalent scFv. All our in vitro data argue 
for a potential in vivo use of scFvD2B; therefore, imaging in vivo experiments 
with both fluorescent-scFvD2B and radiolabeled-scFvD2B were performed.  
 
7 In vivo Imaging  
 
Procedures involving animals and care were in conformity with institutional 
guidelines that comply with national and international laws and policies (D.L. 
116/92 and subsequent implementing circulars).  
 
8 Imaging with fluorescinated antibodies 
 
Mice bearing established s.c. PC3 (PSMA negative) and PC3-PIP (ectopically 
expressing PSMA) tumors were used for in vivo tumor detection capability 
(visualized by optical imaging) of both IgGD2B and scFvD2B labeled with a 
fluorochrome. The two fluorescinated reagents present different tumor detecting 
kinetics and biodistribution patterns (Fig. 12). IgGD2B initially showed a very 
diffuse signal involving both tumors while 24 hours after injection was possible 
to identify a specific accumulation of the antibody in PC3-PIP cells. 
Conversely, scFvD2B 3 hours after injection is able to show a detectable sign 
specific for PC3-PIP cells indicating a very high specificity. The high binding 
strength of scFvD2B seems to be enough to have rapid localization despite a 
very fast clearance usually showed for scFvs. The different tumor 
biodistribution of scFvD2B and IgGD2B could be explained by the fact that the 
IgGD2B is initial retained by Fc-receptors on many cell types in the mouse and 
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consequently this leads to the loss of high amount of the initial dose by non-
specific binding through those receptors, which is not without systemic side 
effects, whereas the use of scFvD2B, lacking the Fc portion, do not have this 
broad and diffuse effect. By reducing the size of antibody below the filtration 
threshold of kidneys (70 kDa) the renal excretion is increased and therefore a 
decreased toxicity to this organ is expected when radioconiugated scFv are 
used. Moreover small size antibody fragments enabled a fast distribution into 
the tumor and a quick clearance from the blood and other compartments 
reducing also in this case the potential radiotoxic damage to healthy tissue. 
These in vivo experimental data documented the ability of scFvD2B to 
specifically target only PSMA expressing PCa xenografts indicating that our 
reagent could be an ideal antibody fragment for the development of novel 
diagnostic/therapeutic methods to target imaging agents or for delivery of drugs 
for treatment of PSMA-positive tumors. 
9 In vivo localization using 131I – and 111In-scFvD2B 
 
The choice of the radioisotopes for imaging and therapy is also important 
because catabolism of the radiolabeled-reagent is different. 
It is known that when an antigen rapidly internalize after binding with the 
antibody, the complex is endocytosed and delivered to the lysosomes. 
Antibodies 111-In labeled after reaching the lysosomes can be hydrolyzed to 
small molecular weight compounds by the resident enzymes, retained by 
lysosome and slowly released from the cells. On the contrary for antibodies 
131I-labeled after degradation into the lysosomes, the low molecular weight 
catabolites produced are rapidly expelled from cells reducing the possible 
background effect created by the retention of the radioisotope. 
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PC3-PIP cells and PC3 cells were mixed with matrigel and the mixtures were 
injected subcutaneously in CD1 nude mice in the shoulder. Tumors reached 
dimension suitable for scintigraphy after 20 days.  
131I – or 111In-scFvD2B were injected intravenously into mouse tail. 
Scintigraphy was performed 24 hours after injection and static images were 
acquired for 30 minutes. 131I – or 111In-scFvD2B biodistribution was calculated 
after 6 and 24 hours post injection calculating the radioactivity in tumors and 
representative organs.  
The two radiolabeled reagents present different tumor detecting patterns.  111In-
scFvD2B shows a very high accumulation into the kidneys, for this reason no 
localization of scFvD2B is detectable in scintigraphy. This data is also 
confirmed by the biodistribution analysis (Fig.13A) in which the kidney T/B is 
about 1000 cpm (at 24 hours post injection) and the tumor T/B is about 12 cpm 
(at 24 hours post injection). When 131I is used, the biodistribution analysis 
(Fig.13B) indicate a similar accumulation of scFvD2B in the site of the tumor 
and a very low background on the kidney (Fig.13B, left panel), therefore no 
localization were detected in mice inoculated with PC3 cells (Fig.13B, middle 
panel). The low background of kidneys allowed to visualize a specific 
localization on tumor (PC3-PIP cells) by scintigraphy (Fig.13B, right panel).  
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Conclusion and Future Prospects 
 
The results obtained in this thesis demonstrate that the PSMA-specific 
internalizing scFvD2B, due to its advantageous properties, may be an ideal 
antibody fragment for the development of novel diagnostic/therapeutic methods 
to target imaging agents or for delivery of drugs for treatment of PSMA-
positive tumors. 
To be able to use a scFv for targeting in humans, the reagent will be further 
improved in order to enter in Phase I clinical trial. ScFvD2B genes will be 
cloned into a specific vector (lacking the two tags: Myc-tag and His-tag 
normally fused to a COOH-terminal) for the expression in mammalian cells. 
ScFvD2B without tags will be characterized and the preclinical experiments, 
once radiolabeled, performed with the aim to propose it as radiolabeled 
diagnostic for PCa imaging and dosimetry in a Phase I clinical study. 
Moreover, the high stability of the molecule argues for further exploitation of 
scFvD2B to generate fusion proteins and build mono-specific multimeric or bi-
specific reagents that, upon preclinical validation, could hopefully enter into 
clinical use. 
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Figures 
 
 
 
 
Fig. 1. Gel filtration on size-exclusion column. Purified scFvD2B preparation contains at least 
95% of monomeric molecules (one representative experiment of 5 performed is shown). 
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Fig. 2. A) FACS analysis: scFvD2B (solid line) binding in comparison to that IgGD2B (dashed 
line) on PSMA positive cell lines (LnCaP, MCF7-hPSMA, CHO-hPSMA and PC3-hPSMA). 
No binding was observed on PSMA negative cell lines (MCF7, CHO, PC3)). The shift in 
fluorescence was assessed relative to a negative control (gray).   
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Fig. 3. A) IHC: ScFvD2B reactivity of prostate carcinoma. Images on serial cryostat sections 
from left to right: hematoxylin-eosin stained sections (4x); scFvD2B immunohistochemical 
stain (10x) showing no reactivity on healthy component and positive reaction on tumor 
component in the same section; magnification 20x and 40x of normal component; magnification 
20x and 40x of tumor component. B) BIAcore analysis: (left panel) binding of scFvD2B 
(26RU) is only apparently lower than that observed with IgGD2B (88 RU) since its size is 6 
times lower than that of the entire mAb; (right panel) Kinetic analyses of scFvD2B. 
 
 
Fig.4. Integrity of scFvD2B before and after radiolabeling compared with IgGD2B. Left panel, 
SDS-PAGE loaded with cold scFvD2B (well 1) and IgGD2B (well 3) and with scFvD2B (well 
2) and radiolabeled IgGD2B (well 4). Right panel, the same samples after autoradiography. 
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Tab 1. Summary of scFvD2B and IgGD2B characteristics after radiolabeling with 131I and 111In. 
 
 
 
 
Fig. 5. Competition assay: 131I-scFvD2B (A) or 131I-IgGD2B (B) were mixed with titrated doses 
of unlabeled scFvD2B, IgGD2B, IgG7E11 or IgGJ591 and incubated on PC3-PIP cells. 
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Fig. 6. Integrity of scFvD2B in human (A) and mouse (B) serum. SDS-PAGE Autoradiography 
loaded with 131I-scFvD2B after mixture in human and mouse serum from t=0 to 24 hours. 131I-
scFvD2B diluted in PBS was added as control. The same result was obtained with 111In-
scFvD2B (data non shown).   
 
 
 
 
Fig. 7. Stability analysis. Unlabeled scFvD2B or 131I / 111In labelled scFvD2B stability in mouse 
(A) and human (B) serum at 37°C. 
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Fig. 8.  ELISA assay. Binding on PC3-PIP cells of scFvD2B in serial dilutions after storage at 
 -20 °C from T=0 to 18 months.  
 
 
 
Fig. 9. SDS-PAGE (left panel). Integrity of scFvD2B and scFvD2B-NOTA after one hour at 
42°C in comparison with non treated reagents; ELISA assay (right panel). The functionality of 
the same reagents was tested for binding capability in serial dilutions on PC3-PIP cells. 
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Fig. 10. ELISA assay. Binding of scFvD2B after exposure to low pH (scFvD2B in PBS and in 
HEPES pH7 were added as control). 
 
 
 
 
Fig. 11. Internalization ability of scFvD2B and IgGD2B. A) fluorescent reagents incubated at 
37°C (left panel) and 4°C (right panel). B) radiolabeled scFvD2B (solid lane) and IgGD2B 
(dashed lane).  
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Fig. 12. CYS5 ScFvD2B and IgGD2B in vivo biodistribution. Localization of IgGD2B (A, 
upper panels) or scFvD2B (A, lower panels); B) Histograms report the relative total photons 
emitted from regions of interest around tumor sites from mice injected with IgGD2B (upper 
panel) or scFvD2B (lower panel). 
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Fig. 13. Radiolabeled scFvD2B in vivo biodistribution. A) Biodistribution of 111In-scFvD2B. B) 
Scintigraphy of 131I-scFvD2B (left panel); Biodistribution of 131I-scFvD2B on blood and tumor 
on PC3 and PC3-PIP cells (middle panel); Biodistribution of 131I-scFvD2B in all organs 
examinated but only on PC3-PIP cell (right panel). Histograms report the relative total cpm 
emitted from regions of interest. (T/B: tissue/blood ratio). 
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PART III 
 
Creation of a completely human antibody fragment starting from the 
monoclonal antibody D2B.
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Results and Discussion 
 
1 Selection of human antibody fragments by panning with magnetic beads 
 
The second part of my project is the creation of a completely human antibody 
fragment against PSMA. All the data obtained in the first part of my thesis 
demonstrate that scFvD2B have adequate functionality, specificity and binds, 
with good affinity, to an epitope different from those recognized by the other 
anti-PSMA antibodies commercially available. These characteristic make 
scFvD2B an ideal reagent for diagnostic and therapeutic practices.  In order to 
reduce the potential immunogenicity of the reagent but maintain similar 
antigen-binding characteristics of the starting monoclonal antibody D2B, the 
guided selection procedure (also called epitope imprinting selection) has been 
used for the conversion of the murine antibody into completely human antibody 
fragments. This method uses a murine chain (in our case the light chain) to 
drive the selection of the other chain (in our case the VHCH). With this method, 
the murine variable domains are sequentially replaced by human variable 
domains. The antibody phage selection was performed on soluble PSMA after 
its immobilization using IgG anti-mouse beads for the binding of IgG7E11 that 
recognize the intracellular domain of PSMA. The first round of selection is the 
most important. Any errors made at this point will be amplified in subsequent 
rounds of selection. 
It was calculated that after each round of selection there is a 103 fold 
enrichment of specific antibody. Ideally, only one cycle of selection should be 
required, but sometimes the binding of non-specific phages, due to their 
stickiness, limits their enrichment. For this reason 3-5 rounds of selection 
should be performed to select the desired antibody. In our cases three rounds of 
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selection were performed with different experimental conditions in order to 
select PSMA-specific phages. The hybrid polyclonal phages (composed by 
human VHCH1 and murine VKCK-D2B) recovered after each panning cycles 
were screened for binding by ELISA in order to identify "polyclonal" phage 
antibodies. ELISA was performed on PC3-PIP and PC3 cell lines. As shown in 
figure 14A there was an enrichment of binding capability with further rounds of 
selection and the binding is specific, in fact no binding was observed on PC3 
cells (data not shown) indicating that the process was working. 
Single clone phage ELISA was performed starting from randomly picked single 
colonies to identify positive "monoclonal" phage antibodies.  
29 clones demonstrated ability to bind PC3-PIP and not the negative PC3 cell 
lines. Among those positive clones we identified two different heavy chains 
named VHCH-A and VHCH-B. The two corresponding genes were cloned into 
a vector containing a library of human light chains genes (VKCK). In this way 
the two human VHCH1 selected could drive the selection of a suitable human 
VKCK. Three panning cycles were performed as previous described. The 
polyclonal phages obtained after each panning were tested in ELISA but no 
evidence of binding improvement was found (Fig. 14B). Moreover from the 
single clone phage ELISA no clones with PSMA specificity were found (data 
not shown).  
  
2 Binding of antibody fragments A and B 
 
To try to understand why we failed to select a suitable light chain we hypothize 
that our VHCH could be able alone to bind the antigen and for that reason the 
VH selected are not able to drive selection of VL because not necessary. It is in 
fact described in literature [Harmsen and de Haard2007] that some antibody 
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chains alone are enough to bind the antigen and many groups started to study 
the so called single-domain antibodies or nanobodies demonstrating the 
functionality of VH alone. 
Our failure in light chain selection could suggest that probably for some heavy 
chain the possible presence of a light chain could interfere with antigen binding. 
To confirm our hypothesis the two selected clones (clone A and clone B) have 
been built as VHCH1 or VH domain. 
To determine whether VHCH-A and VHCH-B are specific for PSMA in 
absence of light chain, the antibody fragments were expressed on phage surface 
and tested in ELISA in comparison with the Fab format associated with the 
murine light chain. ELISA showed that hVHCHs have a higher binding than the 
respective Fabs (Fig. 15A) giving the proof that the heavy chain alone are able 
to bind the antigen and probably the presence of the light chain may decrease 
the strength of binding. 
To verify whether soluble anti-PSMA hVHCHs retained the binding properties 
of the hVHCHs displayed on phages, soluble production of VHCH-A and 
VHCH-B were performed after cloning of the corresponding genes into a pUC 
vector. The periplasmic extract was analyzed in DOT-BLOT for production 
(Fig. 15B) and in ELISA to verify the functionality. No binding was observed 
on cells expressing PSMA (data not shown). A plausible interpretation of this 
observation is that when an antibody fragment is displayed on phage, it is more 
stable and/or it acquires a different conformation with a higher stability, which 
enhances its binding properties. Another explanation is that, phages may 
express more copies of the antibody fragments. This may increase the antibody 
valency with enhanced binding of the VHCH expressed on phage surface. 
Moreover the production in soluble form, as showed by DOT BLOT, indicates 
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a low yield of these fragments in the periplasm (at least for VHCH-B), which is 
probably not sufficient to see a binding. 
 
3 VH-A and VH-B binding 
 
To investigate whether VHs domain are able to bind PSMA, the hVH genes 
were re-amplified with the appropriate primers and cloned into a phagemid 
vector that allow the production of both phages and soluble proteins. VH-A and 
VH-B expressed on phage surface were tested on ELISA and FACS analysis 
but no evidence of specific binding was observed (data not shown). The 
periplasmic extract of VH-A and VHB were produced, analyzed in DOT-BLOT 
to verify the production and in FACS to verify the functionality in soluble 
format. The result of the binding on PC3-PIP cells was negative. Because the 
DNA encoding the VHs was cloned into the pIT2 vector fused to a COOH-
terminal hexahistidine sequence, recombinant VHs were purified by 
immobilized-metal affinity chromatography by using Ni-NTA agarose column. 
Purified VH-A and VH-B were tested on FACS analysis and a specific binding 
on PC3-PIP cell lines was observed (Fig.16) whereas no binding was observed 
on negative cells PC3 (data not shown). FACS analysis repeated after few days 
demonstrate a decreased binding indicating a problem in the stability of our 
fragments probably due to a formation of aggregates that is common for this 
kind of antibody fragments (Fig.16).  
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4 Mutagenesis 
 
It is known that human heavy chains, that are naturally associated with the light 
chains, are less stable in its absence because the hydrophobic surface exposed 
confers to the antibody fragment  a poor solubility and a tendency to aggregate. 
Nevertheless it is described that in addition to the conventional antibodies, 
camelids and sharks also produce unusual antibodies composed only of heavy 
chains lacking the light chain. 
In order to improve the solubility of our antibody fragments we decided to 
compare the differences between the heavy chains produced by camelids, that 
were evolved naturally lacking a light chain, and our heavy chains. By 
comparative analysis with VHH domains of Camelidae we found that some 
aminoacidic residues that are normally involved in binding with light chain, in 
camelids are different than in humans conferring more hydrophilicity to the 
molecule. The residues Val37, Gly44, Leu45, and Trp47 are all conserved in 
human VH framework 2 and seems to be involved in interdomain contacts; 
these amino acid residues in original VHH domains of Camelidae, are 
substituted by hydrophilic residues Phe37, Glu44, Arg45 and Gly47. Therefore, 
to mimic the VHH of Camelidae, single and multiple amino acid substitutions 
were introduced into VHCH-A and VHCH-B using the QUIKCHANGE XL 
SITE-DIRECTED MUTAGENESIS KIT (Stratagene). We constructed a set of 
three mutants for each clone with gradual increasing “camelization”. In mutant 
A/37 the Val37 residue in VHCH-A framework 2 was substituted by Phe37. In 
mutant A/44, Gly44, Leu45 and Trp47 in framework 2 were substituted by 
Glu44, Arg45 and Gly47, respectively. In mutant A/D, the four mutations 
described above (V37F, G44E, L45R and W47G) were all introduced into the 
VHCH-A. The same mutations were introduced in VHCH-B (called B/37- 
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B/44- B/D). All six mutants were expressed in the periplasm, the yields of 
soluble mutated clones were similar of the non mutated clones (data not shown) 
and all modifications of the VHCHs showed a weak effect on the stability (data 
not shown), reduced specific binding to PC3-PIP and increased non specific 
binding on PC3 cells as showed in figure 17. At this point of the research we 
evaluated the possibility to introduce more mutations to stabilize the antibody 
fragments, in fact in literature are described other residues that could be 
modified to improve the stability of human VHCH1 including also the insertion 
of 2 cysteins at the positions 22 and 92 that allows the formation of an 
intradomain disulfide bridge. But, as our goal was to produce a human antibody 
fragment, in order to obtain a reagent less immunogenic as possible we decided 
to avoid further modifications residues that could potentially increase the 
immunogenicity.  
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Conclusion and Future Prospects  
 
The results obtained in this part of the project demonstrate that the isolated 
human VHs are able to bind PSMA in native form but that they are not stable. 
More stability studies need to be performed in order to obtain a suitable reagent 
with desirable properties for biopharmaceutical development. 
To this aim we will proceed into two directions:  
A) stabilization of the already isolated VH; 
B) selection of new fragments using different methods.  
A) Two approach are under evaluation: first, a company called GlyTec, Inc has 
been contacted that will study the possibility to stabilized the two VH selected 
using different human oligosaccharides; second, in nature are described some 
light chains called “universal light chains” associated to heavy chains but not 
involved in the binding with the antigen as demonstrated by their high 
similarity to the germline sequence. We plan to associate this human light chain 
to our VHs and evaluate if this is sufficient to stabilize our molecules. 
B) In order to overcome the selection of antibody fragments prone to aggregate, 
the strategy that will be performed was first described by Greg Winter group 
[Jespers et al. 2004] and it is based on heat denaturation of the library 
expressing the antibody fragment followed by panning and selection as usual in 
order to select in origin more stable antibody fragments.  
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Figures 
 
Fig. 14. Polyclonal Phage ELISA. Binding of original library, 1°, 2° and 3° round of selection 
phages composed by human VHCH associated to murine VLCL (A) and by human VHCH 
associated to human VKCK (B). 
 
 
 
Fig. 15.  A) ELISA assay. Binding comparison between phages expressing only VHCH-A or -B 
versus phages expressing VHCH-A or –B associated with murine VKCK D2B. B) DOT BLOT 
analysis. Evaluation of production in bacteria periplasm or in surnatant culture of soluble 
VHCH-A and soluble VHCH-B 
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Fig. 16. FACS analysis. Binding comparison between soluble VH-A and VH-B tested 
immediately after production (fresh production) and after one week (old production). The shift 
in fluorescence was assessed relative to a negative control (gray). 
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Fig. 17. ELISA assay. Binding of soluble VHCH-A and VHCH-B after the introduction of 
mutations. 
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